Diagnostic and prognostic importance of venous thromboembolism in ovarian cancer
Abstract
Background: Cancer and its chemotherapy are well known risk factors for venous thromboembolism. The later can be the first sign of an occult malignancy, especially if it is recurrent one. Venous thromboembolism is also a common cause of morbidity and mortality among cancer patients. In time of the first presentation of venous thromboembolism in the context of underlying cancer the advanced stage of cancer is usually present and this is associated with poor prognosis. Ovarian cancer which is diagnosed within four months after an episode of venous thromboembolism is usually in advanced stages with more aggressive biological properties.
Conclusions: Low-molecular-weight-heparins are the cornerstone of treatment and prophylaxis of venous thromboembolism associated with cancer for the first 3 to 6 months after acute venous thromboembolic event. In accordance with current consensus they are replaced with oral anticoagulants after 6 months of treatment. According to recent trials lowmolecular- weight-heparins cause less side effects and there are less recurrent venous throm boembolisms than with peroral anticoagulant therapy. Accordingly their impact on improved survival of cancer patients is under intensive research. Unfortunately, there is currently no screening test for ovarian cancer which would lead to improved survival.
Downloads
References
Wang X, Fu S, Freedman RS, Kavanagh JJ. Venous thromboembolism syndrome in gynecological cancer. Int J Gynecol Cancer 2006; 16 Suppl 1: 458–71.
Prandoni P, Lensing AW, Buller HL, Cogo A, Prins MH, Cattelan AM, et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992; 327: 1128–33.
Baron JA, Gridley G, Weiderpass E, Nyren O, Linet M. Venous thromboembolism and cancer. Lancet 1998; 351: 1077–80.
Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation 2003; 107: I-17–21.
Agnelli G. Venous thromboembolism and cancer: a two-way clinical association. Thromb Haemost 1997; 78: 117–20.
Fennerty A. Venous thromboembolic disease and cancer. Postgrad Med J 2006; 82: 642–8.
Von Tempelhoff GF, Niemann F, Schneider DM, Kirkpatrick CJ, Hommel G, Heilmann L. Blood rheology during chemotherapy in patients with ovarian cancer. Thromb Res 1998; 90: 73–82.
Prandoni P, Piccioli A. Venous thromboembolism and cancer: a two-way clinical association. Front Biosci 1997. Dosegljivo na: http://www.bioscience.org/1997/v2/e/prandon1/htmls/list.htm
Hettiarachchi RJ, Lok J, Prins MH, Buller HR, Prandoni P. Undiagnosed malignancy in patients with deep vein thrombosis: incidence, risk indicators, and diagnosis. Cancer 1998; 83: 180–5.
Aderka D, Brown A, Zelikovski A, Pinkhas J. Idiopathic deep vein thrombosis in an apparently healthy patient as a premonitory sign of occult cancer. Cancer 1986; 57: 1846–9.
Monreal M, Fernandez-Llamazares J, Perandreu J, Urrutia A, Sahuguillo JC, Contel E. Occult cancer in patients with venous thromboembolism: which patients, which cancers. Thromb Haemost 1997; 78: 1316–8.
Rajan R, Levine M, Gent M, Hirsh J, Geerts W, Skingley P, et al. The occurrence of subsequent malignancy in patients presenting with deep vein thrombosis: results from a historical cohort study. Thromb Haemost 1998; 79: 19–22.
Ahmed Z, Mohyuddin Z. Deep vein thrombosis as a predictor of cancer. Angiology 1996; 47: 261–5.
Luxembourg B, Bauersachs R. Malignancy and thrombosis: a double-sided clinical relationship. Vasa 2005; 34: 225–34.
Prandoni P, Piccioli A. Thrombosis as a harbinger of cancer. Curr Opin Hematol 2006; 13: 362–5.
Prandoni P. Cancer and venous thromboembolism. Clinical implications of strong association. Pathophysiol Haemost Thromb 2006; 35: 111–5.
Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol 2005; 6: 401–10.
Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100: 3484–8.
Levine M. Low-molecular-weight heparin or oral anticoagulation for secondary prevention of deep vein thrombosis in cancer patients. Semin Thromb Hemost 2003; 29 Suppl 1: 9–11.
Prins MH, Hettiarachchi RJ, Lensing AW, Hirsh J. Newly diagnosed malignancy in patients with venous thromboembolism. Search or wait and see? Thromb Haemost 1997; 78: 121–5.
Pruemer J. Prevalence, causes, and impact of cancer-associated thrombosis. Am J Health Syst Pharm 2005; 22 Suppl 5: S4–6.
Sack GH Jr, Levin J, Bell WR. Trousseau’s syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore) 1977; 56: 1–37.
White RH, Chew HK, Zhou H, Parikh-Patel A, Harris D, Harvey D, et al. Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Arch Intern Med 2005; 165: 1782–7.
Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334: 677–81.
Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343: 1846–50.
Sorensen HT, Johnsen SP, Norgard B, Zacharski LR, Baron JA. Cancer and venous thromboembolism: a multidisciplinary approach. Clin Lab 2003; 49: 615–23.
Rickles FR, Levine MN. Epidemiology of thrombosis in cancer. Acta Haematol 2001; 106: 6–12.
Von Tempelhoff GF, Dietrich M, Niemann F, Schneider D, Hommel G, Heilmann L. Blood coagulation and thrombosis in patients with ovarian malignancy. Thromb Haemost 1997; 77: 456–61.
Thodiyil P, Kakkar AK. Can low-molecular-weight heparins improve outcome in patients with cancer? Cancer Treat Rev 2002; 28: 151–5.
Von Tempelhoff GF, Heilmann L, Hommel G, Schneider D, Niemann F, Zoller H. Hyperviscosity syndrome in patients with ovarian carcinoma. Cancer 1998; 82: 1104–11.
Tetsche MS, Norgaard M, Pedersen L, Lash TL, Sorensen HT. Prognosis of ovarian cancer subsequent to venous thromboembolism:
a nationwide Danish cohort study. BMC Cancer 2006; 6: 189.
Sorensen HT, Mellemkjaer L, Steffensen FH, Olsen JH, Nielsen GL. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 1998; 338: 1169–73.
Tateo S, Mereu L, Salamano S, Klersy C, Barone M, Spyropoulos AC, et al. Ovarian cancer and venous thromboembolic risk. Gynecol Oncol 2005; 99: 119–25.
Murchison JT, Wylie L, Stockton DL. Excess risk of cancer in patients with primary venous thromboembolism: a national, population- based cohort study. Br J Cancer 2004; 91: 92–5.
Canney PA, Wilkinson PM. Pulmonary embolism in patients receiving chemotherapy for advanced ovarian cancer. Eur J Cancer Clin Oncol 1985; 21: 585–6.
Lee AY, Levine MN. The thrombophilic state induced by therapeutic agents in the cancer patient. Semin Thromb Hemost 1999; 25: 137–45.
Recio FO, Piver MS, Hempling RE, Driscoll DL. Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum-based chemotherapy. Cancer 1996; 78: 2157–63.
Toyoda M, Satoh T, Takano K, Sato NO, Oki A, Tsunoda H, et al. Successful diagnosis of thromboembolism before surgery in a woman with clear cell adenocarcinoma of the endometrium. Int J Clin Oncol 2005; 10: 444–6.
Kaneuchi M, Sasaki M, Tanaka Y, Shiina H, Yamada H, Yamamoto R, et al. WT1 and WT1-AS genes are inactivated by promoter methylation in ovarian clear cell adenocarcinoma. Cancer 2005; 104: 1924–30.
Pather S, Quinn MA. Clear-cell cancer of the ovary-is it chemosensitive? Int J Gynecol Cancer 2005; 15: 432–7.
Chan JK, Loizzi V, Lin YG, Osann K, Brewster WR, DiSaia PJ. Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important? Obstet Gynecol 2003; 102: 156–61.
Pavelka JC, Brown RS, Karlan BY, Cass I, Leuchter LS, Lagasse LD, et al. Effect of obesity on survival in epithelial ovarian cancer. Cancer 2006; 107: 1520–4.
Jacobs I, Davies AP, Bridges J, Stabile I, Fay T, Lower A, et al. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. BMJ 1993; 306: 1030–4.
Tailor A, Bourne TH, Campbell S, Okokon E, Dew T, Collins WP. Results from an ultrasound-based familial ovarian cancer screening clinic: a 10-year observational study. Ultrasound Obstet Gynecol 2003; 21: 378–85.
Stirling D, Evans DG, Pichert G, Shenton A, Kirk EN, Rimmer S, et al. Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the international Federation of gynecology and obstetrics system. J Clin Oncol 2005; 23: 5588–96.
Olivier RI, Lubsen-Brandsma MA, Verhoef S, van Beurden M. CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer. Gynecol Oncol 2006; 100: 20–6.
Cornuz J, Pearson SD, Creager MA, Cook EF, Goldman L. Importance of findings on the initial evaluation for cancer in patients with symptomatic idiopathic deep venous thrombosis. Ann Intern Med 1996; 125: 785–93.
Prandoni P, Piccioli A, Pagnan A. Recurrent thromboembolism in cancer patients: incidence and risk factors. Semin Thromb
Hemost 2003; 29 Suppl 1: 3–8.
Prandoni P. How I treat venous thromboembolism in patients with cancer. Blood 2005; 106: 4027–33.
Büller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126: 401S–428S.
Goodin S. Selecting an anticoagulant for recurrent venous thromboembolism in cancer. Am J Health Syst Pharm 2005; 22 Suppl 5: S10–3.
Laza-Achille M, Desruennes E, Di Palma M. Treatment of venous thrombosis in cancer patients: practical aspects. Bull Cancer 2006; 93: 271–81.
Peternel P. Uvodno in nadaljevalno zdravljenje venske tromboze. In: Urlep-Šalinović V, ed. Hemostatske motnje – strokovno srečanje ob 30-letnici hemostaziološke dejavnosti v Splošni bolnišnici Maribor; 2006 Maj 26; Maribor, Slovenija.
Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Low-molecular-weight heparin versus coumarin for the prevention of recurrent venous thromboembolism in cancer. N Engl J Med 2003; 349: 146–53.
Lee AY, Rickles FR, Julian JA, Gent M, Baker RI, Bowden C, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005; 23: 2123–9.
Kher A, Samama MM. Primary and secondary prophylaxis of venous thromboembolism with low-molecular-weight heparins: prolonged thromboprophylaxis, an alternative to vitamin K antagonists. J Thromb Haemost 2005; 3: 473–81.
Pruemer J. Treatment of cancer-associated thrombosis: distinguishing among antithrombotic agents. Semin Oncol 2006; 2 Suppl 4: S26–39.
Levine MN, Lee AY, Kakkar AK. From Trousseau to targeted therapy: new insights and innovations in thrombosis and cancer. J Thromb Haemost 2003; 1: 1456–63.
Zacharski LR, Prandoni P, Monreal M. Warfarin versus low-molecular- weight heparin therapy in cancer patients. Oncologist 2005; 10: 72–9.
Klerk CP, Smorenburg SM, Otten HM, Lensing AW, Prins MH, Piovella F, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005; 23: 2130–5.
Kakkar AK, Levine MN, Kadziola Z, Lemoine NR, Low V, Patel HK, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004; 22: 1944–8.
Burris HA 3rd. Low-molecular-weight heparins in the treatment of cancer-associated thrombosis: a new standard of care? Semin Oncol 2006; 2 Suppl 4: S3–16.
Cunningham RS. The role of low-molecular-weight heparins as supportive care therapy in cancer-associated thrombosis. Semin Oncol 2006; 2 Suppl 4: S17–25.
Norrby K. Low-molecular-weight heparins and angiogenesis. APMIS 2006; 114: 79–102.
Noble SI, Nelson A, Turner C, Finlay IG. Acceptability of low molecular weight heparin thromboprophylaxis for inpatients receiving palliative care: qualitative study. BMJ 2006; 332: 577–80.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
